Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Renagel Marketing Message Will Focus On Lipid-Lowering Effect

This article was originally published in The Pink Sheet Daily

Executive Summary

Phosphate binder may face competition from Shire’s Fosrenol and Amgen’s cinacalcet in the near term. Genzyme views cinacalcet as a "complementary product" rather than a direct competitor.

You may also be interested in...



Shire's Fosrenol Gets FDA Nod, Will Be Available By Year-End

Fosrenol will compete directly with Genzyme's Renagel; both products are non-calcium, non-aluminum containing phosphate binders. Shire estimates that less than one-third of the 800,000 ESRD patients with elevated phosphate levels are able to control their phosphorus levels with existing medications.

Shire's Fosrenol Gets FDA Nod, Will Be Available By Year-End

Fosrenol will compete directly with Genzyme's Renagel; both products are non-calcium, non-aluminum containing phosphate binders. Shire estimates that less than one-third of the 800,000 ESRD patients with elevated phosphate levels are able to control their phosphorus levels with existing medications.

Abbott Will Grow Zemplar Sales With Oral Formulation, Predialysis Use

An NDA filing for oral Zemplar in predialysis chronic kidney disease patients is slated for this summer. Amgen's Sensipar will have "no effect" on the Zemplar I.V. business, Abbott says.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel